Purification and enzymatic characterization of the hepatitis B virus ribonuclease H, a new target for antiviral inhibitors

被引:21
|
作者
Villa, Juan Antonio [1 ,2 ]
Pike, Daniel P. [1 ,2 ]
Patel, Kunjan B. [1 ,2 ]
Lomonosova, Elena [1 ,2 ]
Lu, Gaofeng [1 ,2 ,3 ]
Abdulqader, Roz [1 ,2 ]
Tavis, John E. [1 ,2 ]
机构
[1] St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA
[2] St Louis Univ, Sch Med, St Louis Univ Liver Ctr, St Louis, MO 63104 USA
[3] Zhengzhou Univ, Affiliated Hosp 2, Dept Gastroenterol, Zhengzhou, Henan, Peoples R China
关键词
Hepatitis B virus; DNA virus; RNA processing; Ribonuclease; Endoribonuclease; STRAND DNA-SYNTHESIS; RNASE-H; REVERSE-TRANSCRIPTASE; RNA/DNA HYBRID; VIRAL-DNA; HIV-1; RT; POLYMERASE; REPLICATION; DOMAIN; EXPRESSION;
D O I
10.1016/j.antiviral.2016.06.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hepatitis B virus (HBV) reverse transcription requires coordinated function of the reverse transcriptase and ribonuclease H (RNaseH) activities of the viral polymerase protein. The reverse transcriptase has been biochemically characterized, but technical difficulties have prevented both assessment of the RNaseH and development of high throughput inhibitor screens against the RNaseH. Expressing the HBV RNaseH domain with both maltose binding protein and hexahistidine tags led to stable, high-level accumulation of the RNaseH in bacteria. Nickel-affinity purification in the presence of Mg2+ and ATP removed co-purifying bacterial chaperones and yielded nearly pure monomeric recombinant enzyme. The endonucleolytic RNaseH activity required an DNA:RNA duplex >= 14 nt, could not tolerate a stem-loop in either the RNA or DNA strands, and could tolerate a nick in the DNA strand but not a gap. The RNaseH had no obvious sequence specificity or positional dependence within the RNA, and it cut the RNA at multiple positions even within the minimal 14 nt duplex. The RNaseH also possesses a processive 3'-5' exoribonuclease activity that is slower than the endonucleolytic reaction. These results are consistent with the HBV reverse transcription mechanism that features an initial endoribonucleolytic cut, 3'-5' degradation of RNA, and a sequence-independent terminal RNA cleavage. These data provide support for ongoing anti-RNaseH drug discovery efforts. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:186 / 195
页数:10
相关论文
共 50 条
  • [41] Synthesis of hemslecin A derivatives: A new class of hepatitis B virus inhibitors
    Guo, Rui-Hua
    Geng, Chang-An
    Huang, Xiao-Yan
    Ma, Yun-Bao
    Zhang, Quan
    Wang, Li-Jun
    Zhang, Xue-Mei
    Zhang, Rong-Ping
    Chen, Ji-Jun
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (05) : 1201 - 1205
  • [42] NS5A: A new target for antiviral drugs in the treatment of hepatitis C virus infection
    Debes, Jose D.
    Smith, Coleman I.
    HEPATOLOGY, 2012, 56 (03) : 797 - 799
  • [43] Lipid Metabolite Profiling Identifies Desmosterol Metabolism as a New Antiviral Target for Hepatitis C Virus
    Rodgers, Mary A.
    Villareal, Valerie A.
    Schaefer, Esperance A.
    Peng, Lee F.
    Corey, Kathleen E.
    Chung, Raymond T.
    Yang, Priscilla L.
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2012, 134 (16) : 6896 - 6899
  • [44] Antiviral Evaluation of Dispirotripiperazines against Hepatitis B Virus
    Jones, Thane
    Tavis, John E.
    Li, Qilan
    Riabova, Olga
    Monakhova, Natalia
    Bradley, Daniel P.
    Lane, Thomas R.
    Makarov, Vadim
    Ekins, Sean
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (17) : 12459 - 12467
  • [45] Antiviral therapy and resistance with hepatitis B virus infection
    Hans L Tillmann
    World Journal of Gastroenterology, 2007, (01) : 125 - 140
  • [46] Antiviral therapy and resistance with hepatitis B virus infection
    Tillmann, Hans L.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (01) : 125 - 140
  • [47] Hepatitis B virus mutations associated with antiviral therapy
    Bartholomeusz, A.
    Locarnini, S.
    JOURNAL OF MEDICAL VIROLOGY, 2006, 78 : S52 - S55
  • [48] Hepatitis B virus genotypes and response to antiviral therapy
    Enomoto, M
    Tamori, A
    Nishiguchi, S
    CLINICAL LABORATORY, 2006, 52 (1-2) : 43 - 47
  • [49] Development of antiviral drugs against hepatitis B virus
    Xu, Zaichao
    Zhao, Kaitao
    Jiang, Ying'an
    Xia, Yuchen
    CHINESE SCIENCE BULLETIN-CHINESE, 2019, 64 (30): : 3123 - 3141
  • [50] Antiviral chemotherapy for the treatment of hepatitis B virus infections
    Torresi, J
    Locarnini, S
    GASTROENTEROLOGY, 2000, 118 (02) : S83 - S103